Zanubrutinib
Sign in to save this workspacePrimary targets: BTK · FDA status: FDA Approved
Selectivity scorecard
KISS
98.24
Gini
0.788
CATDS
0.033
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Zanubrutinib. Strongest target: ERBB4_HER4 at 99.6% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERBB4_HER4 | 99.6% | 0.4% |
| 2 | BMX_ETK | 99.3% | 0.7% |
| 3 | BLK | 99.1% | 0.9% |
| 4 | BTK | 97.4% | 2.6% |
| 5 | TXK | 96.9% | 3.1% |
| 6 | TEC | 95.8% | 4.2% |
| 7 | BRK | 93.4% | 6.6% |
| 8 | MEK2 | 89.9% | 10.1% |
| 9 | FGR | 88.4% | 11.6% |
| 10 | EGFR | 88.2% | 11.8% |
| 11 | LCK | 87.3% | 12.7% |
| 12 | YES_YES1 | 85.0% | 15.0% |
| 13 | ITK | 74.5% | 25.4% |
| 14 | CSK | 64.0% | 36.0% |
| 15 | MEK1 | 54.1% | 45.9% |
| 16 | SRMS | 54.0% | 46.0% |
| 17 | FYN | 50.7% | 49.3% |
| 18 | LYN | 50.3% | 49.7% |
| 19 | FLT3 | 47.8% | 52.2% |
| 20 | ERBB2_HER2 | 47.2% | 52.8% |
Selectivity landscape
Where Zanubrutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Zanubrutinib.
Atlas insights for Zanubrutinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target4%
Off-target96%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1379.62 | |
| ALLOGRAFT_REJECTION | 6405.15 | |
| ANDROGEN_RESPONSE | 1159.79 | |
| ANGIOGENESIS | 1151.91 | |
| APICAL_JUNCTION | 6065.27 | |
| APICAL_SURFACE | 648.98 | |
| APOPTOSIS | 3895.94 | |
| BILE_ACID_METABOLISM | 740.03 | |
| CHOLESTEROL_HOMEOSTASIS | 874.88 | |
| COAGULATION | 677.05 | |
| COMPLEMENT | 3663.19 | |
| DNA_REPAIR | 935.45 | |
| E2F_TARGETS | 1894.87 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1079.82 | |
| ESTROGEN_RESPONSE_EARLY | 1501.92 | |
| ESTROGEN_RESPONSE_LATE | 1320.47 | |
| FATTY_ACID_METABOLISM | 514.09 | |
| G2M_CHECKPOINT | 1970.81 | |
| GLYCOLYSIS | 1298.19 | |
| HEDGEHOG_SIGNALING | 488.05 | |
| HEME_METABOLISM | 1101.43 | |
| HYPOXIA | 2232.12 | |
| IL2_STAT5_SIGNALING | 2002.27 | |
| IL6_JAK_STAT3_SIGNALING | 2614.54 | |
| INFLAMMATORY_RESPONSE | 3391.76 | |
| INTERFERON_ALPHA_RESPONSE | 614.97 | |
| INTERFERON_GAMMA_RESPONSE | 3684.23 | |
| KRAS_SIGNALING_DN | 471.66 | |
| KRAS_SIGNALING_UP | 2225.08 | |
| MITOTIC_SPINDLE | 3557.77 | |
| MTORC1_SIGNALING | 2409.99 | |
| MYC_TARGETS_V1 | 1328.80 | |
| MYC_TARGETS_V2 | 225.76 | |
| MYOGENESIS | 1864.66 | |
| NOTCH_SIGNALING | 178.28 | |
| OXIDATIVE_PHOSPHORYLATION | 877.66 | |
| P53_PATHWAY | 1932.71 | |
| PANCREAS_BETA_CELLS | 69.06 | |
| PEROXISOME | 516.76 | |
| PI3K_AKT_MTOR_SIGNALING | 4905.13 | |
| PROTEIN_SECRETION | 1278.77 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 311.96 | |
| SPERMATOGENESIS | 606.05 | |
| TGF_BETA_SIGNALING | 824.61 | |
| TNFA_SIGNALING_VIA_NFKB | 2430.00 | |
| UNFOLDED_PROTEIN_RESPONSE | 608.20 | |
| UV_RESPONSE_DN | 2405.04 | |
| UV_RESPONSE_UP | 2174.58 | |
| WNT_BETA_CATENIN_SIGNALING | 1096.88 | |
| XENOBIOTIC_METABOLISM | 1431.98 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| SRR23303752 | — | 0.821 |
| SRR10899984 | — | 0.813 |
| EPT0291 | EPN | 0.810 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.804 |
| SRR12202498 | — | 0.799 |
Annotations
Sign in to read and post annotations.
Loading…